2 terminated, 1 completed. 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Not applicable | 1 | Completed 1 |
Follow rotigaptide: new trials by email Literature Review of rotigaptide trials Research Report on rotigaptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gap Junction Potentiation of Endothelial Function With Rotigaptide Rotigaptide, Forearm vascular study - Vascular Disease, Heart Disease | Not applicable | Completed | University of Edinburgh | 10 | 2009-03-01 | 2021-06-21 |
| Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia | Phase 2 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 90 | 2005-11-01 | 2007-12-10 |
| Study Evaluating GAP-486 in Heart Rhythm GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia | Phase 2 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 30 | 2005-11-01 | 2007-12-10 |
Arrhythmias, Cardiac (2) · Heart Diseases (1) · Syncope (1) · Vascular Diseases (1)
Wyeth is now a wholly owned subsidiary of Pfizer (2) · University of Edinburgh (1)
Canada (2) · United States (2) · United Kingdom (1)